Global Bridges at Mayo Clinic and Pfizer Global Medical Grants
Quality Improvement Request for Proposals (RFP)
Raising Awareness and Promoting Timely Diagnosis of TTR Amyloidosis
Date RFP Issued

18 March 2024

Background andPurpose of this RFP

Amyloidosis is often misdiagnosed. For example, it is estimated that the correct diagnosis
of TTR amyloidosis is delayed by years, in part because it is a multisystemic disorder. Our
goal is to help accelerate this patient journey by supporting capacity building programs.
In recent years, Global Bridges at Mayo Clinic and Pfizer Global Medical Grants havesupported independent projects focused on raising awareness and closing knowledge gaps
to reduce the time it takes for patients to be correctly diagnosed and make treatment
more accessible, while supporting the development of a global network of TTR
amyloidosis experts. Expanding the community of practice will help decrease the distancepatients need to travel to be diagnosed, although valuable guidance may still be obtained
from experienced centers further from home. This RFP is a continuation of this program.
It is not our intent to support research projects. Any research projects will be consideredout of scope for this project. Examples of out-of-scope projects include clinical research
projects, basic science research, prevalence studies, registry development, health services
research and outcomes research.

Geographic Scope

Global (not including the United States)

Funding andAdministration ofProjects

Project proposals will be reviewed and recommended by an expert advisory panel.
Projects selected for funding will be funded directly by Pfizer Inc.

Applicant Eligibility

Applications are invited from institutions, organizations or associations, e.g. professional
schools, hospitals, healthcare systems, universities, patient advocacy groups, professional
associations, government agencies

Operational and technical support for funded projects will be provided by Mayo Clinic.

Grants can only be awarded to organizations, not individuals or medical practice groups.

Clinical Area

TTR Amyloidosis (any organ system)

1
Global Bridges Amyloidosis Request for Proposals 2024 (Global ex-US)

Characteristics of a
Successful Proposal

In order to increase the capacity of the health care system to provide more timely
diagnosis and appropriate treatment to TTR amyloidosis sufferers in any organ, we areinterested in receiving proposals that:••••••

Reduce the time to correct diagnosis, among a broad audience of health care
professionals, including increasing coordination across specialties; AND
Build on evidence and international best practice; AND
Include a robust and well-defined plan for evaluation and dissemination; AND
Support the development of a global network of health care professionals capableof diagnosing and treating TTR amyloidosis, AND
Support the development of a global network of TTR amyloidosis experts
Include a plan to sustain the project beyond the period of funding.

Out of Scope of thisCall

It is not our intent to support research projects. Projects evaluating the efficacy oftherapeutic or diagnostic agents will not be considered. Additional examples of out-ofscope projects include clinical research projects, basic science research, prevalence
studies, registry development, health services research and outcomes research.

Funding
Available/MaximumAward Levels

Total funding available for this RFP is US $225,000. We anticipate funding 3 projects.

How to Submit

1. Please go to http://www.cybergrants.com/pfizer/QI and sign in. First-time users shouldclick “Create your password”.
2. Select the following Primary Area of Interest: TTR Amyloidosis
3. Select the following Competitive Grant Program Name: 2024 RD G Raising Awareness &Promoting Timely Diagnosis of TTR Amyloidosis
4. Complete all required sections of the online application. See Appendix A for details.

Timing

Proposals must be completed in the CyberGrants system no later than Thursday, 2 May,
2024.
All applicants will be notified of the outcome of their application by email in September,
2024. Applicants may also be contacted to provide further clarification in order to support
the review of this application.
If your grant is approved, your institution will be required to enter into a written grant
agreement with Pfizer. Please click here to view the core terms of the agreement. The
agreement is expected to be signed by both parties within 2024 and without change.
Anticipated project start date for funded projects is early 2025.

QuestionsIf you have any questions regarding this RFP, or to discuss whether your project would bein scope, please contact Katie Kemper at Global Bridges (kemper.katherine@mayo.edu) or
the Pfizer Grant Officer, Amanda Stein (amanda.j.stein@pfizer.com).

2
Global Bridges Amyloidosis Request for Proposals 2024 (Global ex-US)

** OVERVIEW OF QUALITY IMPROVEMENT PROPOSALREQUIREMENTS ON FOLLOWING PAGES**

3
Global Bridges Amyloidosis Request for Proposals 2024 (Global ex-US)

Raising Awareness and Promoting Timely Diagnosis of TTR Amyloidosis
Quality Improvement Proposal Requirements
Applications will be accepted via the online portal (www.cybergrants.com/pfizer/QI). All sections of yourapplication will need to follow the character limits specified in the online application.*:Goals andObjectives

Briefly state the overall goal and objectives of the proposed project

Assessment of
Need for theProject

Please include a quantitative baseline data summary, initial metrics (e.g., qualitymeasures), or a project starting point (please cite data on gap analyses or relevant
patient-level data that informs the stated objectives) in your target area.
Describe the source and method used to collect the data. Describe how the data wereanalyzed to determine that a gap existed. If a full analysis has not yet been conducted,
please include a description of your plan to obtain this information.

Target Audience

Describe the primary audience(s) targeted for this project. Also indicate whom youbelieve will directly benefit from the project outcomes. Describe the overall population
size as well as the size of your sample population.

Project Design andMethods

Outline the proposed methodology and key stages or milestones of your planned
approach. Maximum project length is two years.

Innovation

Evaluation andOutcomes•

Explain what measures you have taken to assure that this project idea is original
and does not duplicate other projects or materials already developed.

•Describe how this project builds upon existing work, pilot projects, or ongoingprojects developed either by your institution or other institutions related to thisproject.

Describe how you will measure the success of your project. What measures and metrics
will you use to evaluate the impact of the project? Describe your plan to capturebaseline and end-of-project metrics and results. Example metrics include:•••

Number of health care professionals trained
Number of patients diagnosed with TTR Amyloidosis
Number of patients receiving intervention

4
Global Bridges Amyloidosis Request for Proposals 2024 (Global ex-US)

Anticipated
Project Timeline

Provide an anticipated timeline for your project including project start/end dates

Additional
Information

Educational Sustainability: How will the results of the project be shared? How will theproject support ongoing improvement in amyloidosis treatment and training?

Organizational
DetailDescribe the mission, capability, and relevant previous activity of the applicant
organization and how it will facilitate the project. Also include information aboutcollaborating or project-partner organizations as applicable.

Monetary Request

Please indicate total monetary amount being requested for this project in United States
Dollars (USD).
While estimating your budget please keep the following items in mind:
oInstitutional overhead and indirect costs may be included within the grant
request. Examples include human resources department costs, payroll
processing and accounting costs, janitorial services, utilities, property taxes,property and liability insurance, and building maintenance as well as additional
project expenses such as costs for publication, IRB / IEC review fees, software
license fees, and travel. Please note: Pfizer does not provide funding for capitalequipment.

oPfizer maintains a company-wide, maximum allowed overhead rate of 28% forindependent studies and projects. Please click here for details.

oIt should be noted that grants awarded through GMG cannot be used topurchase therapeutic agents (prescription or non-prescription).

*The online application also includes the fields noted above. The text in those fields should be
the same text that is included in your Full Proposal document.

5
Global Bridges Amyloidosis Request for Proposals 2024 (Global ex-US)